Last edition
News about "CDMO and Specialty Pharma Drive Growth"
Jubilant Pharmova Ltd reported a strong performance for the first quarter of FY26, with its consolidated net profit rising 48% year-on-year to INR 60 crore, up from INR 41 crore in Q1 FY25. Total revenue for the quarter grew 10% to INR 1,650 crore, compared to INR 1,500 crore in the corresponding period last year.
CDMO And Specialty Pharma Drive Growth | 30/07/2025 | By Darshana | 409
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members